Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. The company’s lead program, NRM‑823, is a T cell engager with tumor-specific targeting for multiple solid tumors and is expected to enter the clinic in 2025. Normunity is located in Boston, MA, and New Haven, CT.
Company Details
- Employees
- 24
- Address
- Untapped Biology At The Interface Of The Immune System And The Tumor To Target Mechanisms That Impact Tumor Growth And Circumvent Immune Surveillance And Tumor Clearance. The Company Is Using These Novel Targets To Build A Pipeline Of Anti-Cancer Medicines
- Industry
- Biotechnology
- Website
- http://www.normunity.com/
Normunity Questions
Normunity's website is http://www.normunity.com/
Normunity's LinkedIn profile is https://www.linkedin.com/company/normunity
Normunity has
24 employees.
View email and phone details for 24
employees at Normunity.
Normunity's industry is
Biotechnology
Normunity's top competitors are
Tenvie Therapeutics,
Numab Therapeutics Ag,
Ouro Medicines,
Umoja Biopharma,
Tune Therapeutics,
Windward Bio,
Kardigan,
Timberlyne Therapeutics,
Light Horse Therapeutics,
Be Biopharma.
Normunity's categories are Biotechnology
